Treatment Interruption and Discontinuation in Radiotherapy for Rectal Cancer

Author： Lebwohl Benjamin Ballas Leslie Cao Yin Chan Galant Grossman Reuven Sherr David L. Woodhouse Shermian Neugut Alfred I.

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.28, Iss.3, 2010-03, pp. : 289-294

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

ABSTRACTRadiotherapy with chemotherapy for rectal cancer reduces local recurrence risk. Of 113 patients (59 male, 54 female) undergoing treatment at New York Presbyterian Hospital, 1998–2007, 6 discontinued radiotherapy; all were female. Females were also more likely to have a treatment interruption (35% vs 12%, p = .004). Other factors associated with treatment interruption included adjuvant versus neoadjuvant therapy (OR 14.08, 95%CI 1.55–127.87), use of capecitabine versus 5-fluorouracil (OR 75.90, 95%CI 3.33–>999), and development of any adverse event (OR 20.66, 95%CI 1.76–242.12). While radiotherapy discontinuation was uncommon in our cohort, for unknown reasons, females were more likely to discontinue or interrupt treatment.